Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2014-07-03FDA Approved: BENICAR — Supplemental Application (Cosette Pharmaceuticals, Inc.)
FDA approved a supplemental application for Benicar (olmesartan medoxomil) submitted by Cosette Pharmaceuticals, Inc.
-
FDA label_change · 2014-05-06FDA Approved: PROCARDIA XL — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for Procardia XL (nifedipine) from Pfizer Laboratories to update the product labeling.
-
FDA label_change · 2014-05-06FDA Approved: TOPROL XL — Supplemental Application (Melinta Therapeutics, LLC)
FDA approved a supplemental application for TOPROL XL (metoprolol succinate) filed by Melinta Therapeutics, resulting in labeling changes fo…
-
FDA label_change · 2013-11-05FDA Approved: ZESTORETIC — Supplemental Application (Almatica Pharma Inc.)
FDA approved a supplemental application for ZESTORETIC (lisinopril and hydrochlorothiazide) by Almatica Pharma Inc., resulting in changes to…
-
FDA label_change · 2013-11-05FDA Approved: ZESTRIL — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for ZESTRIL (lisinopril) submitted by Upsher-Smith Laboratories, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2013-09-20FDA Approved: BYSTOLIC — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Bystolic (nebivolol hydrochloride) submitted by Allergan, Inc., resulting in labeling updates fo…
-
FDA label_change · 2013-07-24FDA Approved: NORVASC — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Norvasc (amlodipine besylate) resulting in updates to the product labeling.
-
FDA label_change · 2013-05-16FDA Approved: EPLERENONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Eplerenone by Mylan Pharmaceuticals, typically indicating labeling updates.
-
FDA label_change · 2013-04-26FDA Approved: DOXAZOSIN — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for DOXAZOSIN (doxazosin mesylate) by Teva Pharmaceuticals USA, Inc., indicating an approved modific…
-
FDA label_change · 2013-02-05FDA Approved: INDAPAMIDE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for indapamide from Actavis Pharma, resulting in labeling changes for the product.
-
FDA label_change · 2012-11-16FDA Approved: NORVASC — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for NORVASC (amlodipine besylate) filed by Viatris Specialty LLC.
-
FDA label_change · 2012-10-31FDA Approved: ZESTRIL — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for Zestril (lisinopril) from Upsher-Smith Laboratories, resulting in updated labeling.
-
FDA label_change · 2012-10-26FDA Approved: AVALIDE — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA supplemental application for AVALIDE (irbesartan and hydrochlorothiazide) submitted by Sanofi-Aventis U.S. LLC, typically for labeling u…
-
FDA label_change · 2012-08-13FDA Approved: ZESTORETIC — Supplemental Application (Almatica Pharma Inc.)
FDA supplemental approval for ZESTORETIC (lisinopril and hydrochlorothiazide) submitted by Almatica Pharma Inc. to update the product label.
-
FDA label_change · 2012-07-11FDA Approved: FUROSEMIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for furosemide from Chartwell RX, LLC, resulting in changes to the drug's labeling.
-
FDA label_change · 2012-05-17FDA Approved: LOTENSIN — Supplemental Application (Validus Pharmaceuticals LLC)
FDA approved a supplemental application for Lotensin (benazepril hydrochloride) filed by Validus Pharmaceuticals LLC.
-
FDA label_change · 2012-02-17FDA Approved: ENALAPRIL MALEATE — Supplemental Application (OCEANSIDE PHARMACEUTICALS)
The FDA approved a supplemental application for enalapril maleate (Oceanside Pharmaceuticals), resulting in a labeling update for the produc…
-
FDA label_change · 2012-02-16FDA Approved: EXFORGE HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)
A supplemental application for Exforge HCT (amlodipine, valsartan, and hydrochlorothiazide) submitted by Novartis Pharmaceuticals Corporatio…
-
FDA label_change · 2012-01-18FDA Approved: MICARDIS — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental labeling change for Micardis (telmisartan) submitted by Boehringer Ingelheim Pharmaceuticals, Inc.
-
FDA label_change · 2012-01-18FDA Approved: AVALIDE — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for Avalide (irbesartan and hydrochlorothiazide) from Sanofi-Aventis U.S. LLC.
-
FDA label_change · 2011-11-17FDA Approved: HYZAAR — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for HYZAAR, a fixed-dose combination of losartan potassium and hydrochlorothiazide, submitted by…
-
FDA label_change · 2011-10-31FDA Approved: EXFORGE — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for EXFORGE (amlodipine besylate and valsartan) from Novartis Pharmaceuticals Corporation.
-
FDA label_change · 2011-06-03FDA Approved: EXFORGE HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for EXFORGE HCT (amlodipine/valsartan/hydrochlorothiazide) from Novartis, updating the product label…
-
FDA label_change · 2011-06-03FDA Approved: DIOVAN HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Diovan HCT (valsartan and hydrochlorothiazide) filed by Novartis Pharmaceuticals Corporation. Th…
-
FDA label_change · 2011-05-31FDA Approved: EXFORGE — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for EXFORGE (amlodipine besylate and valsartan) by Novartis Pharmaceuticals Corporation. The act…